Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 8/20 | 0.38 |
| ▸ | CTSK | P43235 | 8/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255697 | 0.81 | TDP1 (0.45) | MEN1KMT2AALDH1A1TSHRHCRTR2 | |
| SCHEMBL22604487 | 0.81 | MEN1 (0.42) | MEN1KMT2AALDH1A1TSHRHCRTR2 | |
| SCHEMBL8253836 | 0.81 | HCRTR2 (0.42) | CTSLMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL8256590 | 0.80 | HCRTR2 (0.41) | MEN1KMT2AALDH1A1TSHRHCRTR2 | |
| SCHEMBL8230389 | 0.80 | HCRTR2 (0.41) | MEN1KMT2AALDH1A1TSHRHCRTR2 | |
| SCHEMBL25317380 | 0.80 | CTSL (0.43) | CTSLMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL31432022 | 0.80 | HCRTR2 (0.41) | CTSLMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL22604486 | 0.80 | HCRTR2 (0.41) | MEN1KMT2AALDH1A1TSHRHCRTR2 | |
| SCHEMBL27343898 | 0.80 | HCRTR2 (0.41) | CTSLMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL10163707 | 0.78 | HCRTR2 (0.40) | CTSLMEN1KMT2AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240150334-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20040058857-A1 | Method of treating cancer | YAO SIU-LONG (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1009420-B1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO INC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| US-20030215456-A1 | Method of treating cancer | YAO SUI-LONG (US) | 2003-11-20 | — | — | US | disclosed |
| US-20020173451-A1 | Method of treating cancer | YAO SUI-LONG (US) | 2002-11-21 | — | — | US | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | disclosed |
| US-6127333-A | COMPRISING OLIGOPEPTIDES, HAVING AMINO ACID SEQUENCES THAT ARE SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN AND KNOWN CYTOTOXIC AGENTS, CHARACTERIZED BY A DIAMINE LINKER BETWEEN THE OLIGOPEPTIDE AND VINBLASTINE | MERCK & CO., INC. (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | CTSL 973/4885MEN1 783/4885KMT2A 1240/4885 |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | CTSL 2803/4885MEN1 4182/4885KMT2A 1081/4885 |
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | CTSL 770/4885MEN1 707/4885KMT2A 2337/4885 |
| US-20040058857-A1 | Method of treating cancer | KLK3, SHBG, ACP3 | CTSL 859/4885MEN1 276/4885KMT2A 1984/4885 |
| US-20240150334-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | HSD17B1, HSD17B3, HSD17B13 | CTSL 1793/4885MEN1 3752/4885KMT2A 2873/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | CTSL 63/4885MEN1 3090/4885KMT2A 3548/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | CTSL 63/4885MEN1 3090/4885KMT2A 3548/4885 |
| US-20030215456-A1 | Method of treating cancer | TACR1, TACR2, KLK3 | CTSL 433/4885MEN1 521/4885KMT2A 995/4885 |
| US-20020173451-A1 | Method of treating cancer | FOLH1, KLK3, ACP3 | CTSL 175/4885MEN1 993/4885KMT2A 1907/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CTSL 63/4885MEN1 3090/4885KMT2A 3548/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | CTSL 623/4885MEN1 859/4885KMT2A 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.